---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-286248"
form_type: "8-K"
ticker: "DCTH"
cik: "0000872912"
company_name: "DELCATH SYSTEMS, INC."
filed_at: "2024-12-30T23:59:59+00:00"
generated_at: "2026-05-28T22:57:56.806347+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Delcath Systems receives $16.3M from Series E and E1 warrant exercises

## Summary
- 1,746,424 warrants exercised; 1,045,157 shares of common stock and 603,954 pre-funded warrants issued.
- Gross proceeds of approximately $16.3 million; ~6.6% of exercises were cashless.
- Warrants had $10.00 exercise price, issued in July/August 2019, expired Dec 24, 2024.
- CEO states cash position strong to fund HEPZATO commercialization and clinical trials.
- Warrant amendments allow pre-funded warrants to avoid exceeding 9.99% beneficial ownership cap.

## SEC filing metadata
- accession: 0001193125-24-286248
- form_type: 8-K
- ticker: DCTH
- cik: 0000872912
- company_name: DELCATH SYSTEMS, INC.
- filed_at: 2024-12-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/872912/000119312524286248/0001193125-24-286248-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/872912/000119312524286248/d924758d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-286248
- JSON: https://secwatch.observer/filing/0001193125-24-286248.json
- Plain text: https://secwatch.observer/filing/0001193125-24-286248.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.